Last edition
News about "IgA nephropathy "
Novartis Presents Interim Analysis of atrasentan Phase III Data
Novartis has presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN).
IgA Nephropathy | 28/05/2024 | By Aishwarya | 132
Vertex Signs Agreement to Acquire Alpine Immune Sciences
Vertex Pharmaceuticals has signed a definitive agreement with Alpine Immune Sciences, a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
IgA Nephropathy | 11/04/2024 | By Aishwarya | 200
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy